CAMBRIDGE, MA, PineTree Therapeutics announced that the company has raised $23.5 million for Series A1 funding.
PineTree Therapeutics, an emerging leader in pioneering the development of disruptive therapies in Oncology, Immuno-oncology and other diseases, announced that the company has raised $23.5 Million for Series A1 funding. The investments, which will be used to advance our Oncology and Viral Diseases platforms, were made by InterVest, SK Securities, DSC Investment, J Curve Investment, Samho Green Investment, and SJ Investment Partners.
PineTree Therapeutics is a pre-clinical stage Biotech company headquartered in Cambridge, MA and was founded in 2019. It has developed the TAER-TAB and ViTRAP technologies and is building a broad pipeline for hard-to-treat cancers and viral diseases, with an initial focus on oncology.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.